Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

ClinicalTrials.gov ID: NCT00782626

Public ClinicalTrials.gov record NCT00782626. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas

Study identification

NCT ID
NCT00782626
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Dana-Farber Cancer Institute
Other
Enrollment
23 participants

Conditions and interventions

Interventions

  • everolimus Drug

Drug

Eligibility (public fields only)

Age range
3 Years to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2009
Primary completion
Jul 31, 2012
Completion
Jul 31, 2012
Last update posted
Aug 14, 2018

2009 – 2012

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
9
Facility City State ZIP Site status
Phoenix Children's Hospital Center for Cancer and Blood Disorders Phoenix Arizona 85016
The Children's Hospital Denver Colorado 80045
University of Florida College of Medicine Gainesville Florida 32610
Children's Healthcare of Atlanta Atlanta Georgia 30322
John Hopkins Medical Center Baltimore Maryland 21231
Dana-Farber Cancer Institute Boston Massachusetts 02115
New York University New York New York 10016
Memorial Sloan-Kettering Cancer Institute New York New York 10174
Doernbecher Children's Hospital Oregon Health & Science University Portland Oregon 97239
Seattle Cancer Care Alliance Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00782626, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 14, 2018 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00782626 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →